Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,262
  • Shares Outstanding, K 38,052
  • Annual Sales, $ 10 K
  • Annual Income, $ -29,870 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.42

Options Overview Details

View History
  • Implied Volatility 75.56% (-65.46%)
  • Historical Volatility 104.17%
  • IV Percentile 3%
  • IV Rank 1.65%
  • IV High 1,095.90% on 12/10/25
  • IV Low 58.49% on 09/08/25
  • Expected Move (DTE 2) 2.34 (89.56%)
  • Put/Call Vol Ratio 10.00
  • Today's Volume 11
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,226
  • Open Int (30-Day) 1,132
  • Expected Range 0.27 to 4.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.23
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +2.35%
on 01/13/26
4.99 -47.68%
on 01/05/26
-1.70 (-39.44%)
since 12/12/25
3-Month
2.55 +2.35%
on 01/13/26
8.53 -69.40%
on 11/05/25
-2.67 (-50.57%)
since 10/14/25
52-Week
1.99 +31.32%
on 04/09/25
8.53 -69.40%
on 11/05/25
+0.22 (+9.21%)
since 01/14/25

Most Recent Stories

More News
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.61 (-4.74%)
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten...

GNLX : 2.61 (-4.74%)
Genelux Corporation Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a...

GNLX : 2.61 (-4.74%)
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment...

GNLX : 2.61 (-4.74%)
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten,...

GNLX : 2.61 (-4.74%)
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.61 (-4.74%)
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026...

GNLX : 2.61 (-4.74%)
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO...

GNLX : 2.61 (-4.74%)
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter...

GNLX : 2.61 (-4.74%)
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

GNLX : 2.61 (-4.74%)

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 2.88
2nd Resistance Point 2.81
1st Resistance Point 2.71
Last Price 2.61
1st Support Level 2.54
2nd Support Level 2.47
3rd Support Level 2.37

See More

52-Week High 8.53
Fibonacci 61.8% 6.03
Fibonacci 50% 5.26
Fibonacci 38.2% 4.49
Last Price 2.61
52-Week Low 1.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar